Catalyst
Slingshot members are tracking this event:
FDA Approves ORKAMBI (lumacaftor/ivacaftor) for Use in Children with Cystic Fibrosis Ages 6 through 11 who have Two Copies of the F508del Mutation
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| VRX |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 28, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Orkambi, Lumacaftor, Ivacaftor, Cystic Fibrosis, F508del Mutation
